OncoZenge AB (8LY)
Market Open
12 Aug, 06:08
XFRA XFRA Primary €
0. 55
+0.04
+7.8586%
€
6.67M Market Cap
- P/E Ratio
- Div Yield
2,045 Volume
-1.2 Eps
€ 0.51
Previous Close Want to track 8LY and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
8LY trading today higher at €0.55, an increase of 7.8586% from yesterday's close, completing a monthly decrease of -14.3526% or -€0.09. Over the past 12 months, 8LY stock lost -10.2941%.
8LY is not paying dividends to its shareholders.
The last earnings report, released on May 30, 2024, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on one exchange.
OncoZenge AB (8LY) FAQ
What is the stock price today?
The current price is €0.55.
On which exchange is it traded?
OncoZenge AB is listed on XFRA.
What is its stock symbol?
The ticker symbol is 8LY.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 6.67M.
Has OncoZenge AB ever had a stock split?
No, there has never been a stock split.
OncoZenge AB Profile
| Biotechnology Industry | Healthcare Sector | Mr. Stian Kildal CEO | XFRA Exchange | SE0015504097 ISIN |
| Sweden Country | 1 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
OncoZenge AB (publ) emerges as a pioneering figure in the pharmaceutical sector, specifically focusing on developing treatments aimed at alleviating oral pain endured by cancer patients undergoing radiation therapy and chemotherapy. Established in the year 2020 with its foundation firmly rooted in Bromma, Sweden, the company demonstrates a steadfast commitment towards introducing innovative pain relief solutions. By targeting the acute discomfort experienced in the oral cavity due to aggressive cancer treatments, OncoZenge AB (publ) endeavours to enhance the quality of life for those battling cancer, addressing a critical aspect of their care and wellbeing.
Products and Services
- BupiZenge - At the forefront of OncoZenge AB (publ)’s product lineup stands BupiZenge, a pharmaceutical formulation designed to significantly mitigate pain within the oral cavity. Having successfully completed Phase 2 clinical trials, BupiZenge represents a beacon of hope for patients struggling with severe mouth pain as a consequence of their cancer treatment protocols. This innovative product underscores the company's pivotal role in pioneering pain management solutions tailored for the oncology landscape, showcasing a deep-rooted commitment to improving patient care and outcomes.
Contact Information
Address: GustavslundsvAegen 34
Phone: 46 8 31 14 20
Website: https://oncozenge.com
